Drugs /

bfm regimen

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for bfm regimen

Bfm regimen has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating bfm regimen, 1 is phase 2 (1 open).

BCR-ABL1 Fusion and t(9;22)(q34;q11) are the most frequent biomarker inclusion criteria for bfm regimen clinical trials.

Acute lymphoblastic leukemia is the most common disease being investigated in bfm regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bfm Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bfm regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
berlin-frankfurt-münster protocol, berlin-frankfurt-münster regimen, berlin-frankfurt-münster study group, bfm-sg, bfm protocol, berlin-frankfurt-munster protocol, berlin-frankfurt-munster regimen, berlin-frankfurt-münster chemotherapy, berlin-frankfurt-munster chemotherapy, berlin-frankfurt-munster study group
NCIT ID [1]:
C168888

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.